← Back to all trials
Recruiting
NCT05677711
Safety and Efficacy of the Ultimaster Stent
Conditions: Coronary Artery Disease, Drug-eluting Stents
Sex: All
Ages: 19 Years – N/A
Enrollment: 200
Sponsor: Yonsei University
Location: Korea, Republic of
Summary
Durable polymer was considered to be the cause of a chronic inflammatory response that leadas to impaired endothelialization of the stent strut and subsequently increases the risk of stent thrombosis.
Ultimaster stent (Ultimaster, Terumo Corporation, Tokyo, Japan) are thin strut, silorimus-eluting, biodegradable copolymer to completely degrade over 3-4 months.
Eligibility Criteria
Inclusion Criteria:Age 19 or olderClinical evidence of coronary artery disease, including asymptomatic ischemia, stable angina, and acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction, ST-elevation myocardial infarction)No restrictions on the number of blood vessels, number of lesions, and length of lesionsThose who voluntarily gave written consent to participate in this clinical studyExclusion Criteria:Life expectancy within 1 yearSubjects with known hypersensitivity or contraindications to the following drugs or substances: heparin, aspirin, clopidogrel, prasugrel, ticagrelorIf other researchers judge that it is inappropriate to participate in this study
Source: ClinicalTrials.gov (NCT05677711). StuddyBuddy aggregates publicly available trial information.